Advance in angiogenesis inhibitors in the treatment of non-small cell lung cancer
10.3760/cma.j.issn.1008-1372.2017.06.053
- VernacularTitle:血管生成抑制剂在非小细胞肺癌治疗中的治疗进展
- Author:
Geile NAREN
;
Qing ZHANG
- Keywords:
Angiogenesis inhibitors/TU;
Carcinoma,non-small-cell lung/DT;
Review
- From:
Journal of Chinese Physician
2017;19(6):959-960,封3
- CountryChina
- Language:Chinese
-
Abstract:
Angiogenesis is vital in the process of primary tumor growth,proliferation and metastasis.In many cancers,including non-small cell lung cancer (NSCLC),inhibition of tumor angiogenesis has been identified as an important therapy.The most common drugs include bevacizumab,ramucirumab,tyrosine kinase inhibitor such as sorafenib tosylate,and nintedanib.We will summarize the research about some inhibition of tumor angiogenesis.
